Source: Eur Respir J, 57 (4) 2100224; 10.1183/13993003.00224-2021
Disease area: Airway diseases, Respiratory critical care



Rating:

Share or cite this content

Citations should be made in the following way:
Athena Gogali, Chris Kyriakopoulos, Konstantinos Kostikas. Corticosteroids in COVID-19: one size does not fit all. Eur Respir J, 57 (4) 2100224; 10.1183/13993003.00224-2021

Member's Comments

No comment yet.

Related content which might interest you: Dose-response effect of small particle vs standard size particle inhaled corticosteroids on severe asthma exacerbations by sex Source: International Congress 2015 – Management of asthma and other respiratory diseases in primary care Year: 2015 Acute asthma: large volume spacers are the best Source: Eur Respir J 2005; 26: Suppl. 49, 504s Year: 2005 Forced oscillation technique (FOT) reference values: Does one size fit all? Source: Annual Congress 2012 - Predicting the future: the impact of reference values on a range of respiratory paramaters Year: 2012 Predicting persistence of wheezing: one algorithm does not fit all Source: Eur Respir J 2010; 35: 701-703 Year: 2010 Late Breaking Abstract - Corticosteroid optimisation in severe asthma using composite biomarkers to adjust dose versus a symptom/risk-based algorithm Source: Virtual Congress 2020 – ALERT: Asthma in adults and children Year: 2020 Treatment with inhaled a1-antitrypsin: a square peg in a round hole? Source: Eur Respir J, 54 (5) 1901894; 10.1183/13993003.01894-2019 Year: 2019 Inhaled long-acting β2-agonist: aerosol particle size and bronchodilator response Source: Eur Respir J 2005; 26: Suppl. 49, 126s Year: 2005 Inhaled medication: which device for which patient? Source: Eur Respir Monogr 2015; 69: 213-223 Year: 2015 Extent of inhaled drug deposition at variable inhaler inclination angles and airway geometries: An in-vivo study from a novel computational fluid dynamics model Source: International Congress 2014 – Asthma and COPD devices and treatments Year: 2014 Inhaled corticosteroids in COPD: the final verdict is… Source: Eur Respir J, 52 (6) 1801940; 10.1183/13993003.01940-2018 Year: 2018 Late Breaking Abstract - Influence of salbutamol use on symptomatic outcomes with maintenance bronchodilators: a pre-specified analysis of the EMAX trial Source: International Congress 2019 – New towards old therapies in airway diseases Year: 2019 Getting it right: What does inhaler choice mean for patient outcomes? Source: International Congress 2019 – Putting COPD patient needs first: Time for optimizing treatment and device selection Year: 2019 Lung function in the elderly: time for new reference values? Source: Annual Congress 2009 - Methodological aspects of asthma and COPD epidemiology Year: 2009 Should asthma guidelines be rewritten for initial controller therapy: a 2 year randomized pragmatic equivalence trial of leukotriene antagonists (LTRAs) and inhaled corticosteroids (ICS) in primary care Source: Annual Congress 2008 - Rationale of self-education in asthma therapy Year: 2008 Patient selection? One fits all (monotherapy versus combined therapy)? Source: Sleep and Breathing Conference 2021 Year: 2021 Inhaled steroids and mortality in COPD: bias from unaccounted immortal time Source: Eur Respir J 2004; 24: 190-191 Year: 2004 Inhaled antibiotics: a new tool? Source: Annual Congress 2009 - Antibiotics and the lung Year: 2009